- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05304234
Liver Cancer Disparities in American Indian and Alaska Native Persons
June 13, 2022 updated by: George Ioannou, University of Washington
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
We will compare the aMRI vs. the US arm with respect to the following outcomes:
- Compliance/feasibility of conducting all three screening tests (0, 6 and 12 months) - Primary Outcome
- Proportion of screening tests conducted that employed the appropriate screening protocol and used appropriate documentation of findings with the LI-RADS system - Primary Outcome
- Proportion diagnosed with HCC and stage at diagnosis - Secondary Outcome
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jennifer R Harry
- Phone Number: 206-616-0397
- Email: jharry@medicine.washington.edu
Study Contact Backup
- Name: Stephanie Y Park
- Phone Number: 206-744-7050
- Email: sypark22@uw.edu
Study Locations
-
-
Oklahoma
-
Tahlequah, Oklahoma, United States, 74464
- Recruiting
- Cherokee Nation Health Service
-
Contact:
- Jorge Mera
-
Contact:
- Whitney Essex
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Cirrhosis, any etiology, or chronic HBV infection
- High risk of HCC
- Age 18-75
- Competent to provide informed consent
Exclusion Criteria:
- Prior diagnosis of HCC
- Current suspicion of HCC
- Prior receipt of any organ transplantation
- Participation in another HCC screening trial
- CTP score >=10
- MELD-Na score >20
- GFR<30
- Poor life expectancy (<5 years)
- Contraindication to MRI
- Inability to complete study visits
- Currently pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ultrasound + AFP
Screening by abdominal ultrasound + serum AFP testing at 0, 6 and 12 months
|
Abdominal ultrasound or abbreviated MRI
|
Active Comparator: aMRI + AFP
Screening by abbreviated MRI of the abdomen + serum AFP testing at 0, 6 and 12 months
|
Abdominal ultrasound or abbreviated MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance with screening protocol
Time Frame: 12 months
|
Compliance with conducting all three screening tests
|
12 months
|
Feasibility of screening protocol
Time Frame: 12 months
|
Proportion of screening tests conducted that employed the appropriate screening protocol and used appropriate documentation of findings with the LI-RADS system
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: George Ioannou, MD, MS, University of Washington
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2022
Primary Completion (Anticipated)
April 1, 2024
Study Completion (Anticipated)
April 1, 2025
Study Registration Dates
First Submitted
March 22, 2022
First Submitted That Met QC Criteria
March 22, 2022
First Posted (Actual)
March 31, 2022
Study Record Updates
Last Update Posted (Actual)
June 15, 2022
Last Update Submitted That Met QC Criteria
June 13, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Fibrosis
- Hepatitis
- Hepatitis B
- Liver Cirrhosis
- Liver Neoplasms
Other Study ID Numbers
- STUDY00013583
- 1P20CA252732-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Tongji HospitalGilead SciencesRecruiting
Clinical Trials on Ultrasound or abbreviated MRI
-
University of CambridgeGE Healthcare; Public Health England; Cancer Research UK; Queen Mary University...Recruiting
-
University of ChicagoRecruitingBreast CancerUnited States
-
Seoul National University HospitalGuerbetActive, not recruitingLiver Cirrhosis | Hepatocellular Carcinoma | Chronic HepatitisKorea, Republic of
-
Concord Repatriation General HospitalRecruitingHCC | Hepatocellular CarcinomaAustralia, New Zealand
-
Seoul National University HospitalKorea University Guro Hospital; The Catholic University of Korea; Severance HospitalActive, not recruitingHepatocellular CarcinomaKorea, Republic of
-
University of ChicagoGuerbetCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaUnited States
-
Abramson Cancer Center at Penn MedicineRecruitingPancreatic CancerUnited States
-
Seoul National University HospitalCompletedIntraductal Papillary Mucinous Neoplasm | Pancreas CystKorea, Republic of
-
Angle plcMedical University of Vienna; Charite University, Berlin, Germany; Vivantes Netzwerk...CompletedEvaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.Ovarian NeoplasmsGermany, Austria